Introduction
Tercica is a biopharmaceutical company engaged in developing and marketing a portfolio of endocrinology products. The company was originally created as a company that focused on building a franchise of endocrinology products through partnering with the scientific and medical community to develop and commercialize therapeutics for pediatric and adult growth and metabolic disorders
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Tercica's main focus is to develop and commercialize a portfolio of endocrinology products. It markets only one product, Increlex, a long-term replacement therapy for the treatment of children with severe primary insulin-like growth factor deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Tercica derives its revenues from production and marketing of its own pharmaceutical products and from collaborative agreements consisting primarily of upfront and continuing licensing fees based on the collaboration and license agreement with Ipsen. Tercica's biggest contributor to sales growth out to 2010 will be the sales of Somatuline Depot. Revenues from Somatuline Depot are expected to increase from $2 million in 2007 to $79 million in 2010 contributing approximately 57% of Tercica's total revenues in 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
